ロード中...
Clinical potential of lurasidone in the management of schizophrenia
Lurasidone is a new second-generation antipsychotic approved in October 2010 by the Food and Drug Administration for the treatment of schizophrenia. Like other second-generation antipsychotics, lurasidone is a powerful antagonist of D(2) dopamine and 5HT(2A) serotonin receptors, but differs from the...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3132094/ https://ncbi.nlm.nih.gov/pubmed/21753886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S12701 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|